405 related articles for article (PubMed ID: 25981948)
1. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
Šinigoj P; Malmström RE; Vene N; Rönquist-Nii Y; Božič-Mijovski M; Pohanka A; Antovic JP; Mavri A
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):323-9. PubMed ID: 25981948
[TBL] [Abstract][Full Text] [Related]
2. Real-world variability in dabigatran levels in patients with atrial fibrillation.
Chan NC; Coppens M; Hirsh J; Ginsberg JS; Weitz JI; Vanassche T; Douketis JD; Schulman S; Eikelboom JW
J Thromb Haemost; 2015 Mar; 13(3):353-9. PubMed ID: 25523236
[TBL] [Abstract][Full Text] [Related]
3. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Skripka A; Sychev D; Bochkov P; Shevchenko R; Krupenin P; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):151-156. PubMed ID: 32215878
[TBL] [Abstract][Full Text] [Related]
4. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
5. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
6. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
[TBL] [Abstract][Full Text] [Related]
7. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Legnani C; Antonucci E; Paoletti O; Dellanoce C; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G;
J Thromb Haemost; 2019 Jul; 17(7):1064-1072. PubMed ID: 31013383
[TBL] [Abstract][Full Text] [Related]
8. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Owada S; Tomita H; Kinjo T; Ishida Y; Itoh T; Sasaki K; Horiuchi D; Kimura M; Sasaki S; Okumura K
Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
Martin JL; Esmaeili H; Manuel RC; Petrini M; Wiebe S; Maas H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):399-406. PubMed ID: 29695165
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation.
Lin SY; Tang SC; Kuo CH; Tsai LK; Yeh SJ; Shen LJ; Jeng JS
J Formos Med Assoc; 2019 Jul; 118(7):1154-1160. PubMed ID: 30581104
[TBL] [Abstract][Full Text] [Related]
11. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
Taune V; Wallén H; Ågren A; Gryfelt G; Sjövik C; Wintler AM; Malmström RE; Wikman A; Skeppholm M
Thromb Res; 2017 May; 153():76-82. PubMed ID: 28347811
[TBL] [Abstract][Full Text] [Related]
12. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
13. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
[TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H; Diener HC; Wallentin L; Yusuf S; Connolly SJ
Europace; 2016 Jul; 18(7):973-8. PubMed ID: 26944733
[TBL] [Abstract][Full Text] [Related]
15. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
16. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation.
Boonen K; Schmitz E; Rozestraten F; van den Heuvel D; Brunsveld L; van der Voort P; van de Kerkhof D
Clin Chem Lab Med; 2017 Oct; 55(12):2002-2009. PubMed ID: 28328523
[TBL] [Abstract][Full Text] [Related]
17. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
18. Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
Hantrakun N; Wongcharoen W; Thiankhaw K; Norasetthada L; Tantiworawit A; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Piriyakhuntorn P; Punnachet T; Niprapan P; Chai-Adisaksopha C
J Thromb Thrombolysis; 2023 Feb; 55(2):392-398. PubMed ID: 36484957
[TBL] [Abstract][Full Text] [Related]
19. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
20. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
Kolb JM; Flack KF; Chatterjee-Murphy P; Desai J; Wallentin LC; Ezekowitz M; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
Dig Dis Sci; 2018 Jul; 63(7):1878-1889. PubMed ID: 29582237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
